NuVasive, Inc. (NUVA) News
Filter NUVA News Items
NUVA News Results
|Loading, please wait...|
NUVA News Highlights
- 500 - Internal server error
- Over the past 23 days, the trend for NUVA's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- The most mentioned tickers in articles about NUVA are CE, AGE and AMS.
Latest NUVA News From Around the Web
Below are the latest news stories about Nuvasive Inc that investors may wish to consider to help them evaluate NUVA as an investment opportunity.
The Modulus ALIF 3D-printed porous titanium implant is the latest addition to NuVasive's (NUVA) AMS portfolio for anterior lumbar interbody fusion procedures.
To find a multi-bagger stock, what are the underlying trends we should look for in a business? In a perfect world, we'd...
NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today the commercial launch of Modulus® ALIF, a 3D-printed porous titanium implant for anterior lumbar interbody fusion (ALIF), in targeted global regions.
In this article we will check out the progression of hedge fund sentiment towards NuVasive, Inc. (NASDAQ:NUVA) and determine whether it is a good investment right now. We at Insider Monkey like to examine what billionaires and hedge funds think of a company before spending days of research on it. Given their 2 and 20 […]
NuVasive (NUVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today the Company will release its second quarter 2021 earnings results on Wednesday, July 28, 2021, after the close of the market.
We are upbeat about NuVasive's (NUVA) newly-introduced organizational and leadership structure for its global commercial operations as well as its product and services organization.
The FDA informed healthcare providers of potential biocompatibility concerns with NuVasive Inc's (NASDAQ: NUVA) specialized orthopedics' Precice devices. Precice devices are implants for 18 years of age and older and are used to lengthen the limb, shorten or compress the limb, or transport segments of long bones. They include adjustable rods that are placed inside a patient and are driven by an internal magnetic mechanism. According to an FDA notice, there have been reports describing pain and c
NuVasive (NUVA) announces that the Pulse platform received CE Mark approval for its latest design update; clinical evaluations are underway in multiple countries throughout Europe. "There is a substantial opportunity for enabling technology adoption in spine surgery, and we are leveraging our expertise in proceduralization to introduce Pulse. This next...
NuVasive (NUVA) has announced that its Pulse platform has received CE Mark approval for the latest design update, and clinical evaluations are underway in multiple countries throughout Europe. The approval is considered a key commercialization milestone, expected to pave the way for the company’s expanded global launch this year. With this approved technology, several tools such as radiation reduction, imaging enhancement, rod bending, navigation, intraoperative neuromonitoring, and spinal alignment can be integrated into one platform. Notably, Pulse is expected to increase safety, efficiency, and procedural reproducibility.